Somewhat Positive Media Coverage Somewhat Unlikely to Impact Quidel (QDEL) Stock Price
Press coverage about Quidel (NASDAQ:QDEL) has trended somewhat positive on Saturday, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Quidel earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.8244073333507 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of research analysts have weighed in on the stock. BidaskClub upgraded shares of Quidel from a “sell” rating to a “hold” rating in a research report on Saturday, December 2nd. Zacks Investment Research downgraded shares of Quidel from a “buy” rating to a “hold” rating in a research report on Tuesday, November 7th. Piper Jaffray Companies reiterated a “buy” rating and issued a $50.00 price objective on shares of Quidel in a research report on Friday, November 3rd. Barclays upped their price objective on shares of Quidel from $45.00 to $49.00 and gave the stock an “overweight” rating in a research report on Thursday, November 2nd. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $52.00 price objective (up previously from $48.00) on shares of Quidel in a research report on Thursday, December 21st. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $50.00.
Quidel (QDEL) opened at $46.93 on Friday. The firm has a market cap of $1,579.83, a PE ratio of -312.85, a price-to-earnings-growth ratio of 1.50 and a beta of 1.15. Quidel has a 1 year low of $18.25 and a 1 year high of $47.60. The company has a debt-to-equity ratio of 0.70, a current ratio of 6.28 and a quick ratio of 5.68.
In related news, CEO Douglas C. Bryant sold 12,000 shares of the company’s stock in a transaction dated Friday, December 28th. The shares were sold at an average price of $44.12, for a total transaction of $529,440.00. Following the completion of the transaction, the chief executive officer now owns 286,493 shares in the company, valued at approximately $12,640,071.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jack W. Schuler sold 4,000 shares of the company’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $44.60, for a total transaction of $178,400.00. Following the transaction, the director now owns 3,365,553 shares of the company’s stock, valued at approximately $150,103,663.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 385,790 shares of company stock valued at $15,760,155. Insiders own 22.00% of the company’s stock.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.